Clinical Trial Update: BAY81-8973 Pediatric Safety and Efficacy Trial [Phase 3]

View source ↗

Summary

Phase 3 pediatric trial assessing BAY81-8973 for safety and efficacy in Haemophilia A has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilia

Drugs mentioned

• BAY81-8973 (recombinant coagulation factor VIII)

Snippet

Sponsor: Bayer | Conditions: Haemophilia A | Phase 3 | Status: COMPLETED | Results posted: 2020-11-03